Innoviva, Inc. Common Stock (INVA) Stock Price

INVAStock
$20.97+4.69%52W
Market Cap$1.51B
P/E5.54x
PEG Ratio0.31
Div yield
Beta0.40

INVA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-22.39%
Price vs S&P 500 (4W)-0.58%
PEG Ratio0.31
VGM Score61.99
P/E Ratio (Annual)5.54x

INVA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026$0.50$0.56+11.46%(+$0.06)
Q1 2026$0.43$0.47+8.79%(+$0.04)
Q4 2025$0.42$0.47+11.15%(+$0.05)
Q3 2025$0.39$0.38-0.10%(-$0.00)
Q2 2025$0.50$0.77+54.00%(+$0.27)

INVA Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.09
4.09
4.09
4.09

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
INVAInnoviva, Inc. Common Stock
BBC$20.97
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Innoviva, Inc. Common Stock

Innoviva Inc generates revenue through a portfolio of pharmaceutical royalties and operating assets in critical care and infectious disease. Its holdings include branded respiratory therapies such as Trelegy, Anoro, and the Relvar/Breo/Ellipta franchise, which provide recurring revenue streams from established, marketed products.